Risk for Death, Cardiovascular Death Lower for OSA Patients Using CPAP
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, Sept. 11, 2023 -- For patients with obstructive sleep apnea (OSA), use of continuous positive airway pressure (CPAP) offers cardiovascular (CV) benefits, according to two studies presented at the European Respiratory Society International Congress 2023, held from Sept. 9 to 13 in Milan.
Jordi de Batlle, Ph.D., from the Institut de Recerca Biomèdica de Lleida in Spain, and colleagues examined the impact of CPAP treatment on major CV events in a longitudinal observational study composed of all OSA patients terminating CPAP treatment in 2011 and propensity score-matched OSA patients continuing CPAP treatment (3,638 in each group). The researchers found that after adjustment by age, sex, and key comorbidities, CPAP continuators had a lower risk for CV death than terminators during a median follow-up of 4.5 years (hazard ratio, 0.66). Similar results were seen for CV hospitalizations and for a composite of CV deaths and hospitalizations (hazard ratios, 0.82 and 0.80, respectively).
Cliona O'Donnell, M.B.B.S., from St. Vincent's University Hospital and University College Dublin, and colleagues examined the potential effect of CPAP versus glucagon-like peptide-1 (liraglutide)-mediated weight loss (LWR) on coronary artery plaque volumes in a proof-of-concept study. Thirty patients with moderate-to-severe OSA were randomly assigned to 24 weeks of CPAP, LWR, or a combination. The researchers observed a reduction in low-density coronary artery plaque volume with CPAP and with combination therapy, but not with LWR alone. There was a correlation seen for change in total plaque volume with change in time spent below 90 percent oxygen saturation.
"Although this is a pilot study, meaning we cannot draw firm conclusions, we found improvements in some early signs of cardiovascular disease with CPAP treatment," O'Donnell said in a statement. "This should now be further evaluated in larger studies."
Abstract - O'Donnell
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...
DNA Methylation-Based Epigenetic Age Mediates Link Between LE8 Score, CVD
WEDNESDAY, May 29, 2024 -- The associations between Life's Essential 8 (LE8) and cardiovascular health are mediated by DNA methylation-based epigenetic age, according to a study...
Semaglutide Boosts Kidney Outcomes With Obesity + Cardiovascular Disease
TUESDAY, May 28, 2024 -- Once-weekly subcutaneous semaglutide shows a benefit for kidney outcomes in people with overweight or obesity and established cardiovascular disease...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.